Literature DB >> 31172366

Do systemic steroids increase the risk of ocular complication in uveitis patients? Focus on a Italian referral center.

Chiara Posarelli1, Rosaria Talarico2, Giovanna Vella3, Andrea Passani3, Marta Mosca2, Michele Figus3.   

Abstract

INTRODUCTION: To describe the ocular inflammatory and iatrogenic complications in a cohort of uveitic patients treated in an Italian referral centre.
MATERIAL AND METHODS: Retrospective non-comparative case series. Medical history and clinical findings of all consecutive patients referred to the uveitis center of Pisa University from January 2015 to January 2017 were reviewed. Only patients with at least three follow-up visits in our center were included in our series.
RESULTS: Three hundred and eighty-nine patients were visited in our center during study period; only 142 patients (90 men and 52 female) satisfied the inclusion criteria. Mean age at presentation was 41 ± 14 years. The most common ocular feature was anterior uveitis (46%) and was mainly unilateral. A specific etiological diagnosis was established in 61% of patients. At presentation, 71.43% of patients were on medical therapy for rheumatic disease; 42.86% of patients used systemic steroids Cataract and ocular hypertension were the most common ocular complications during the study period but were not statistically related to systemic steroid treatment.
CONCLUSIONS: Systemic steroids treatment in uveitis patients does not seem to increase the risk of iatrogenic complications such as cataract and glaucoma. In our series, increasing age appears to be the main risk factor for cataract and glaucoma development. Key points • Cataract, ocular hypertension, and glaucoma are the most common iatrogenic complications. • Systemic steroids can be safely used in uveitis patients.

Entities:  

Keywords:  Cataract; Glaucoma; Steroids; Uveitis

Mesh:

Substances:

Year:  2019        PMID: 31172366     DOI: 10.1007/s10067-019-04585-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  35 in total

Review 1.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Authors:  D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum
Journal:  Am J Ophthalmol       Date:  2000-10       Impact factor: 5.258

2.  Incidence and prevalence of uveitis in South Korea: a nationwide cohort study.

Authors:  Tyler Hyungtaek Rim; Sung Soo Kim; Don-Il Ham; Seung-Young Yu; Eun Jee Chung; Sung Chul Lee
Journal:  Br J Ophthalmol       Date:  2017-06-08       Impact factor: 4.638

3.  Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study.

Authors:  K Kotaniemi; H Kautiainen; A Karma; K Aho
Journal:  Ophthalmology       Date:  2001-11       Impact factor: 12.079

Review 4.  Autoimmune uveitis: clinical, pathogenetic, and therapeutic features.

Authors:  Marcella Prete; Rosanna Dammacco; Maria Celeste Fatone; Vito Racanelli
Journal:  Clin Exp Med       Date:  2015-03-28       Impact factor: 3.984

Review 5.  Vitrectomy for Epiretinal Membranes and Macular Holes in Uveitis Patients.

Authors:  Sara V Branson; Brendan R McClafferty; Shree K Kurup
Journal:  J Ocul Pharmacol Ther       Date:  2017-01-23       Impact factor: 2.671

Review 6.  New developments in corticosteroid therapy for uveitis.

Authors:  Simon R J Taylor; Hazlita Isa; Lavnish Joshi; Sue Lightman
Journal:  Ophthalmologica       Date:  2010-08-18       Impact factor: 3.250

Review 7.  Intravitreal steroids for macular edema: the past, the present, and the future.

Authors:  Matthew A Cunningham; Jeffrey L Edelman; Shalesh Kaushal
Journal:  Surv Ophthalmol       Date:  2008 Mar-Apr       Impact factor: 6.048

Review 8.  A Focus on the Epidemiology of Uveitis.

Authors:  Theodora Tsirouki; Anna Dastiridou; Chrysanthos Symeonidis; Ourania Tounakaki; Irini Brazitikou; Christos Kalogeropoulos; Sofia Androudi
Journal:  Ocul Immunol Inflamm       Date:  2016-07-28       Impact factor: 3.070

9.  Biologic agents in inflammatory eye disease.

Authors:  Chiara Posarelli; Ilir Arapi; Michele Figus; Piergiorgio Neri
Journal:  J Ophthalmic Vis Res       Date:  2011-10

Review 10.  Decision-making and management of uveitic cataract.

Authors:  Nicole Shu-Wen Chan; Seng-Ei Ti; Soon-Phaik Chee
Journal:  Indian J Ophthalmol       Date:  2017-12       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.